Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab in moderately to severely active Crohn's disease
NL-OMON60604Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Feb 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3 trial of guselkumab in Crohn's disease, sponsored by Janssen Pharmaceutical. Primary endpoints: Change from baseline in Crohn's Disease Activity Index score at Week 12, Clinical response at Week 12 and clinical remission at Week 48 and 3 more. Started Feb 2019; status: active, not recruiting.
02
Drugs
guselkumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON60604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60604.